Physician profile
Mark R Davis
NPI 1245203702
$463.60
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $106 · 2021: $230 · 2022: $13.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $201.07 | 2020-2022 | |
| Allergan, INC. | $66.67 | 2019 | |
| Avion Pharmaceuticals | $35.92 | 2019-2020 | |
| Roche Diagnostics Corporation | $31.84 | 2021 | |
| Hologic Sales and Service, LLC | $22.59 | 2020-2021 | |
| Duchesnay USA Incorporated | $21.95 | 2019 | |
| Coopersurgical, INC. | $20.86 | 2021 | |
| Dysis Medical, INC. | $19.53 | 2020 | |
| Medicem INC. | $16.66 | 2020 | |
| Amgen INC. | $15.38 | 2020 | |
| Agile Therapeutics, INC. | $11.13 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.